ProfileGDS5678 / 1432956_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 56% 56% 53% 55% 59% 59% 56% 55% 57% 56% 55% 47% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5782659
GSM967853U87-EV human glioblastoma xenograft - Control 23.3969256
GSM967854U87-EV human glioblastoma xenograft - Control 33.4139856
GSM967855U87-EV human glioblastoma xenograft - Control 43.2524553
GSM967856U87-EV human glioblastoma xenograft - Control 53.3106855
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6514459
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6336959
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4010256
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3409555
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4228357
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4091156
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.326855
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1304347
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5444459